Stroke paradox with SGLT-2 inhibitors: A play of chance or a viscosity-mediated reality?

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 88, Issue 3, 2017, Pages 249-253

  Imprialos, Konstantinos P ^a   Boutari, Chrysoula ^a   Stavropoulos, Konstantinos ^a   Doumas, Michael ^b   Karagiannis, Asterios I ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ERTUGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; IPRAGLIFLOZIN; LUSEOGLIFLOZIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TOFOGLIFLOZIN; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD VISCOSITY; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HUMAN; INCIDENCE; KIDNEY TUBULE ABSORPTION; MONOTHERAPY; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; WEIGHT GAIN; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; RISK FACTOR; STROKE;

BENZHYDRYL COMPOUNDS; BLOOD VISCOSITY; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; RISK FACTORS; STROKE;

EID: 85005950931     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2016-314704     Document Type: Review

References (52)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diab Res Clin Prac 2010;87:4-14.
2. Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014;383:2008-17.
3. Panicker GK, Karnad DR, Salvi V, et al. Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs. J Assoc Physicians India 2012;60:56-61.
4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
5. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010;304:411-18.
6. Mahaffey KW, Hafley G, Dickerson S, et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J 2013;166:240-9.
7. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-42.
8. Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015;385:2067-76.
9. Lorber D. GLP-1 receptor agonists: effects on cardiovascular risk reduction. Cardiovasc Ther 2013;31:238-49.
10. Chilton RJ. Potential cardiovascular effects of the glucagon-like peptide-1 receptor agonists. J Diabetes Metab 2015;6:483.
11. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013;159:262-74.
12. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.
13. Wu JH, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2016;4:411-19.
14. Alvarado F, Crane RK. Phlorizin as a competitive inhibitor of the active transport of sugars by hamster small intestine, in vitro. Biochim Biophys Acta 1962;56:170-2.
15. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diab Obes Metab 2012;14:5-14.
16. Vlotides G, Mertens PR. Sodium-glucose cotransport inhibitors: mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease. Nephrol Dial Transplant 2015;30:1272-6.
17. Chao E, Henry R. SGLT2 inhibition-a novel strategy for diabetes treatment. Nat Reviews Drug Disc 2010;9:551-9.
18. Vivian EM. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents. Drugs Context 2014;3:212264.
19. Baker WL, Smyth LR, Riche DM, et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2015;8:262-675.
20. Imprialos KP, Sarafidis PA, Karagiannis AI. Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class? J Hypertens 2015;33:2185-97.
21. Doumas M, Anyfanti P, Bakris G. Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hypertens 2012;30:874-6.
22. Sarafidis PA, Bakris GL. State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens (Greenwich) 2008;10:130-9.
23. Karagiannis A, Hatzitolios AI, Athyros VG, et al. Implementation of guidelines for the management of arterial hypertension. The impulsion study. Open Cardiovasc Med J 2009;3:26-34.
24. Lambers Heerspink HJ, De Zeeuw D, Wie L, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013;15:853-62.
25. Weber MA, Mansfield TA, Alessi F, et al. Effects of dapagliflozin on blood pressure in diabetic patients with hypertension inadequately controlled by a renin-angiotensin system blocker. Circulation 2013;128:A13144.
26. Weber MA, Mansfield TA, T'joen C, et al. Dapagliflozin for reduction of blood pressure in diabetic patients inadequately controlled with combination antihypertensive regimen. Circulation 2013;128:A13165.
27. Townsend RR, Machin I, Ren J, et al. Reductions in mean 24-hour ambulatory blood pressure after 6-week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension. J Clin Hypertens (Greenwich) 2016;18:43-52.
28. Everett BM, Hiatt WR. Finding efficacy in a safety trial: empagliflozin and cardiovascular death. Circulation 2016;134:773-5.
29. Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 2016;37:1526-34.
30. FDA briefing material NDA 204629, and 206111. Food and Drug Administration. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM508422.pdf
31. Sonesson C, Johansson PA, Johnsson E, et al. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol 2016;15:37.
32. EMA assessment report EMA/H/C/002649/0000. European Medicines Agency. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002649/WC500156457.pdf
33. FDA briefing material NDA 204042. Food and Drug Administration. http://www.fda.gov/downloads/AdvistoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.PDF
34. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.
35. Action to Control Cardiovascular Risk in Diabetes Study Group Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
36. ACCORD Study Group Gerstein HC, Miller ME, Genuth S, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364:818-28.
37. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39.
38. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.
39. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338: b1665.
40. ACCORD Study Group Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-85.
41. Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
42. Margolis KL, O'Connor PJ, Morgan TM, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care 2014;37:1721-8.
43. Vemmos K, Ntaios G, Spengos K, et al. Association between obesity and mortality after acute first-ever stroke: the obesity-stroke paradox. Stroke 2011; 42:30-6.
44. Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013;1:208-19.
45. Ridderstråle M, Andersen KR, Zeller C, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2014;2:691-700.
46. Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care 2013;36:4015-21.
47. Gagnon DR, Zhang TJ, Brand FN, et al. Hematocrit and the risk of cardiovascular disease-the Framingham study: a 34-year follow-up. Am Heart J 1994;127:674-82.
48. Lowe GD, Jaap AJ, Forbes CD. Relation of atrial fibrillation and high haematocrit to mortality in acute stroke. Lancet 1983;1:784-6.
49. Pasquini G, Albanese B, Manescalchi PG, et al. [Relation of blood viscosity, plasma viscosity and hematocrit]. Ric Clin Lab 1983;13(Suppl 3):327-31.
50. Lowe GD, Lee AJ, Rumley A, et al. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol 1997;96:168-73.
51. Grotemeyer KC, Kaiser R, Grotemeyer KH, et al. Association of elevated plasma viscosity with small vessel occlusion in ischemic cerebral disease. Thromb Res 2014;133:96-100.
52. Coull BM, Beamer N, de Garmo P, et al. Chronic blood hyperviscosity in subjects with acute stroke, transient ischemic attack, and risk factors for stroke. Stroke 1991;22:162-8.